Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
Stephen Clarke , David Goldstein , Paul Mitchell , Michael Michael
Clinical Colorectal Cancer 6 ( 8) 578 -582
3
2007
Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neurotoxicity
Paul L. Mitchell , David Goldstein , Michael Michael , Philip Beale
Clinical Colorectal Cancer 6 ( 2) 146 -151
35
2006
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker , Louise Nott , Takayuki Yoshino , Sharlene Gill
The Lancet Gastroenterology & Hepatology 3 ( 4) 263 -270
55
2018
Is improving local control sufficient indication for radiotherapy in the management of rectal cancer? A response.
Samuel Y. K. Ngan , David Goldstein , Michael Solomon , John Zalcberg
Anz Journal of Surgery 73 ( 8) 660 -661
2003
Soft tissue metastasis of carcinoid tumour: a rare manifestation
Gerald M. Y. Quan , Alex Pitman , John Slavin , John Zalcberg
Anz Journal of Surgery 74 ( 3) 164 -166
8
2004
Training general practitioners in flexible sigmoidoscopy to screen for colorectal cancer.
Jenepher A. Martin , Brendan Crotty , Dominic Barbaro , Tracey Higlett
Anz Journal of Surgery 71 ( 12) 715 -719
1
2001
Rectal cancer in Victoria in 1994: patterns of reported management.
K. Chip Farmer , Campbell Penfold , Jeremy L. Millar , John Zalcberg
Anz Journal of Surgery 72 ( 4) 265 -270
12
2002
FDG-PET Follow-up of Non-Small Cell Lung Cancer: Not Dead Yet
Rob G. Stirling , John Zalcberg
The Annals of Thoracic Surgery 109 ( 5) 1624
2
2020
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
Val Gebski , Bryan Burmeister , B Mark Smithers , Kerwyn Foo
Lancet Oncology 8 ( 3) 226 -234
1,457
2007
Exploring patient-reported outcomes following percutaneous coronary intervention: A qualitative study
Darshini R. Ayton , Anna L. Barker , Geeske M. E. E. Peeters , Danielle E. Berkovic
Health Expectations 21 ( 2) 457 -465
8
2018
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*
Jaap Verweij , Paolo G Casali , John Zalcberg , Axel LeCesne
The Lancet 364 ( 9440) 1127 -1134
1,369
2004
Relationships among liver and kidney volumes, lean body mass and drug clearance
Sumith Nawaratne , Jo‐anne E. Brien , Ego Seeman , Robert Fabiny
British Journal of Clinical Pharmacology 46 ( 5) 447 -452
53
1998
400a – Effect of Initiating Aspirin on Cancer Events in the Healthy Elderly: Primary Results from the Aspree Randomized Controlled Trial
Andrew T. Chan , Peter Gibbs , Suzanne Orchard , Jessica Lockery
Gastroenterology 156 ( 6)
2019
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Michael Jefford , Michael Michael , Mark A. Rosenthal , Ian D. Davis
Investigational New Drugs 22 ( 2) 185 -192
4
2004
Patients' beliefs about cancer management
John Buchanan , Walter Cosolo , Robyn Millership , Allan Zimet
Supportive Care in Cancer 4 ( 2) 110 -117
22
1996
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database
Qian Shi , Aimery de Gramont , Axel Grothey , John Zalcberg
Journal of Clinical Oncology 33 ( 1) 22 -28
68
2015
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib
Chee Khoon Lee , David Goldstein , Emma Gibbs , Heikki Joensuu
European Journal of Cancer 51 ( 7) 852 -860
17
2015
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
Guillem Argilés , Mark P Saunders , Fernando Rivera , Alberto Sobrero
European Journal of Cancer 51 ( 8) 942 -949
26
2015
The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)
Sue-Anne McLachlan , Richard J. Fisher , John Zalcberg , Michael Solomon
European Journal of Cancer 55 15 -26
32
2016
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Kaitlyn K.H. Goey , Halfdan Sørbye , Bengt Glimelius , Richard A. Adams
European Journal of Cancer 100 35 -45
14
2018